3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Squamous Cell Carcinoma of Head and Neck
4
Pancreatic Neoplasms
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Melanoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Neuroendocrine
1
Anophthalmia with pulmonary hypoplasia
1
Interventions
Bevacizumab
69
atezolizumab
54
durvalumab
43
lenvatinib
42
Nivolumab
38
pembrolizumab
35
tremelimumab
29
Magnetic Resonance Spectroscopy
21
Specimen Handling
19
tislelizumab
18
sintilimab
17
Ipilimumab
15
Sorafenib
14
regorafenib
13
cabozantinib
13
Radiosurgery
13
Radiotherapy
12
apatinib
11
Blood Specimen Collection
11
Immunoglobulin G
10
camrelizumab
9
Immune Checkpoint Inhibitors
9
Disulfides
9
X-Rays
8
Cyclophosphamide
8
donafenib
7
Oxaliplatin
7
Immunotherapy
7
Folfox protocol
7
Fluorouracil
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
budigalimab
×
1 year
×
Clear all
NCT06109272
2025-08-15
LIVIGNO-2
AbbVie
Phase 2/3
Recruiting
660 enrolled
NCT05822752
2025-08-14
LIVIGNO-1
AbbVie
Phase 2
Active not recruiting
130 enrolled